Vera Therapeutics (NASDAQ:VERA) Now Covered by Analysts at The Goldman Sachs Group

The Goldman Sachs Group assumed coverage on shares of Vera Therapeutics (NASDAQ:VERA) in a research report released on Tuesday, Marketbeat Ratings reports. The firm issued a buy rating and a $58.00 price target on the stock.

Other analysts also recently issued reports about the company. Wells Fargo & Company initiated coverage on Vera Therapeutics in a research note on Thursday, November 21st. They set an “overweight” rating and a $70.00 price objective for the company. Wedbush increased their price target on Vera Therapeutics from $30.00 to $38.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. JPMorgan Chase & Co. boosted their price objective on shares of Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Cantor Fitzgerald reiterated an “overweight” rating and set a $107.00 price target on shares of Vera Therapeutics in a research note on Tuesday, October 1st. Finally, Guggenheim raised their price objective on shares of Vera Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research report on Monday, October 28th. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $67.50.

Vera Therapeutics Stock Performance

Shares of Vera Therapeutics stock opened at $35.98 on Tuesday. The firm’s fifty day simple moving average is $42.18 and its 200-day simple moving average is $40.91. Vera Therapeutics has a 12 month low of $29.33 and a 12 month high of $51.61. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of -13.79 and a beta of 1.15. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.21). As a group, equities analysts forecast that Vera Therapeutics will post -2.89 earnings per share for the current year.

Insider Buying and Selling at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 17,500 shares of the business’s stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $41.74, for a total transaction of $730,450.00. Following the sale, the chief executive officer now directly owns 143,603 shares in the company, valued at approximately $5,993,989.22. The trade was a 10.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders sold 52,500 shares of company stock valued at $2,305,625. Corporate insiders own 21.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. grew its stake in Vera Therapeutics by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock valued at $86,000 after acquiring an additional 350 shares during the last quarter. KBC Group NV grew its position in shares of Vera Therapeutics by 127.2% in the fourth quarter. KBC Group NV now owns 2,477 shares of the company’s stock valued at $105,000 after purchasing an additional 1,387 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Vera Therapeutics during the 2nd quarter worth approximately $163,000. AlphaCentric Advisors LLC acquired a new position in shares of Vera Therapeutics during the 3rd quarter worth approximately $332,000. Finally, SG Americas Securities LLC lifted its stake in Vera Therapeutics by 117.5% in the 3rd quarter. SG Americas Securities LLC now owns 9,354 shares of the company’s stock valued at $413,000 after buying an additional 5,053 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.